Recommendation: Buy
Entry Date | Symbol | Recommendation | Entry Price (USD) | Target 1 (USD) | Target 2 (USD) | Holding Duration | Potential Upside |
---|---|---|---|---|---|---|---|
16 Feb, 24 | BAX | Buy | USD 40.89 | USD 44.0 | USD 48.7 | 21 days | 19.1% |
Data Powered by EOD Historical Data (“EODHD”).
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Higher Return on Equity: 0.40% in Q1FY24 vs. 0.30% of Industry Median
Improved Gross Margins: 38.90% in Q1FY24 vs. 37.20% in Q1FY23
Lower Current Ratio: 1.48x in Q1FY24 vs. 3.32x of Industry Median
Lower Net Margins: 1.10% in Q1FY24 vs. 2.1% of Industry Median
Market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.
Entry Price | Support* | Target 1 | Target 2 |
---|---|---|---|
40.89 | 34.0 | 44.0 | 48.7 |
Data Source: REFINITIV, Analysis: StockNextt
*Support can be considered as an indicative stop-loss, and if prices move below that level on closing basis individuals may evaluate exiting the position depending on their risk appetite, previous holdings, and other factors considered. The support and resistance levels may need to be re-evaluated within 4-6 weeks’ time frame depending on the stock price movements from the date of recommendation on the stock.
Financials: Operating Income of the company grew by 45% to USD 187 million during the year, mainly due higher revenue in Q1FY24.
Technical: BAX's stock performance has demonstrated strength as it maintains an upward trajectory along a sloping trendline.
Outlook: The company anticipates sales growth of ~ 2% and adjusted earning per share of USD 2.88 to 2.98 for the full year 2024.
Given the aforementinoed factors, a "Buy" recommendations has been assigned on the stock at the closing market price of USD 40.89 as on 16 February 2024.
Data Powered by EOD Historical Data (“EODHD”).
Sector: Healthcare Industry: Medical Instruments & Supplies
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
BAX Baxter International Inc |
0.36 1.25% | 29.27 | 127.40 | 9.78 | 1.08 | 2.06 | 1.86 | 15.31 |
ISRG Intuitive Surgical Inc |
3.11 0.59% | 529.58 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
ESLOY Essilor International SA |
-0.64 0.53% | 119.68 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
ESLOF EssilorLuxottica Société anonyme |
-3.5 1.44% | 240.00 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
BDX Becton Dickinson and Company |
1.06 0.47% | 225.15 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
Data Powered by EOD Historical Data (“EODHD”).
Note 1: Past performance is neither an indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and target levels is February 16, 2024. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.
Note 4: The report publishing date is as per the Pacific Time Zone.
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Target: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Target 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Target 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer :
This report has been issued by StockNextt which has an Ontario Business Identification Number 1000958347 and British Columbia registration Number FM1051529 is a trade name under Kalkine Canada Advisory Services Inc. having Business Number 761925130BC0001. Kalkine Canada Advisory Services Inc. and StockNextt are collectively referred to as “StockNextt”, “we”, “us”, and “our”. The website https://stocknextt.com and associated pages are published by StockNextt. The information in this report and on the StockNextt website has been prepared from a wide variety of sources, which StockNextt, to the best of its knowledge and belief, considers accurate. StcokNextt has made every effort to ensure the reliability of information contained in its reports, newsletters, and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations for investing in securities and other financial products. StockNextt does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. StockNextt does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. StockNextt’s general advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested. Please also read our Terms and conditions for further information. Employees and/or associates of StockNextt and its related entities may hold an interest in the securities or other financial products covered in this report or on the StockNextt website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Copyright © 2023 Krish Capital Pty Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.